公开(公告)号：US5663202A

公开(公告)日：1997-09-02

申请号：US690545

申请日：1996-07-31

Applicant: David F. Horrobin ,  Catherine A. Scott

Inventor： David F. Horrobin ,  Catherine A. Scott

IPC: A61K31/20 ,  A61K31/202 ,  A61P25/00 ,  A61P43/00

CPC classification number: A61K31/202 ,  A61K31/20

Abstract: Damage to the gastrointestinal tract as a consequence of exposure to ionising radiation is prevented or treated by administration of GLA and/or DGLA. Medicaments containing GLA and/or DGLA for such treatment or prevention may also further comprise EPA and/or DHA.

Abstract translation: 由于暴露于电离辐射而导致的胃肠道损伤通过施用GLA和/或DGLA来预防或治疗。 含有GLA和/或DGLA用于治疗或预防的药物还可以进一步包含EPA和/或DHA。

公开(公告)号：US5635189A

公开(公告)日：1997-06-03

申请号：US297215

申请日：1994-08-29

Applicant: David F. Horrobin ,  Mehar S. Manku

Inventor： David F. Horrobin ,  Mehar S. Manku

IPC: A23L33/15 ,  A61K8/00 ,  A61K8/49 ,  A61K8/67 ,  A61K31/355 ,  A61P3/02 ,  A61Q19/00 ,  C07D311/72 ,  A61K9/14

CPC classification number: C07D311/72

Abstract: A natural vitamin E preparation, i.e. vitamin E extracted from natural sources, comprising one or more of the alpha-, beta-, gamma- and delta-tocopherol forms, either as the tocopherol itself, or as a derivative, such as the acetate, in which the total concentration of Wendt PAHs is less than 100 ppb.

Abstract translation: 天然维生素E制剂，即从天然来源提取的维生素E，其包含α，β，γ和δ-生育酚形式中的一种或多种，​​作为生育酚本身，或作为衍生物，例如乙酸盐， 其中Wendt PAHs的总浓度小于100ppb。

公开(公告)号：US5604216A

公开(公告)日：1997-02-18

申请号：US178553

申请日：1994-01-06

Applicant: David F. Horrobin

Inventor： David F. Horrobin

IPC: A61K8/30 ,  A61K8/00 ,  A61K8/63 ,  A61K31/565 ,  A61K31/575 ,  A61P9/00 ,  A61P9/10 ,  A61P25/00 ,  A61P25/28 ,  A61P27/02 ,  A61P29/00 ,  A61P35/00 ,  A61Q19/00 ,  C07J9/00 ,  A61K31/56

CPC classification number: A61K31/565

Abstract: Pharmaceutical and nutritional compositions are disclosed containing, in association with a suitable diluent or carrier, at least 10% by weight of a cholesterol fatty acid ester where the fatty acid is gamma-linolenic acid, dihomo-gamma-linolenic acid, adrenic acid, the 22:5 n-6 acid, stearidonic acid, the 20:4 n-3 acid, eicosapentaenoic acid, docosahexaenoic acid, the 22:5 n-3 acid or columbinic acid. Novel cholesterol columbinic acid esters are described.

Abstract translation: 公开的药物和营养组合物包含与合适的稀释剂或载体相结合的至少10重量％的胆固醇脂肪酸酯，其中脂肪酸是γ-亚麻酸，二高-γ-亚麻酸，肾上腺素， 22：5 n-6酸，十八碳四烯酸，20：4n-3酸，二十碳五烯酸，二十二碳六烯酸，22：5 n-3酸或哥伦比亚酸。 描述了新型胆固醇骨架酸酯。

公开(公告)号：US5603959A

公开(公告)日：1997-02-18

申请号：US392628

申请日：1995-02-22

Applicant: David F. Horrobin ,  Philip Knowles

Inventor： David F. Horrobin ,  Philip Knowles

IPC: A61K45/00 ,  A61K31/215 ,  A61K31/235 ,  A61K31/405 ,  A61K31/60 ,  A61P13/02 ,  A61P15/00 ,  A61P25/28 ,  A61P29/00 ,  C07C69/86 ,  C07C69/90 ,  C07D209/28 ,  A61K9/14

CPC classification number: C07C69/84 ,  C07C69/86 ,  C07D209/28

Abstract: An NSAID in the form of a compound with an essential fatty acid or essential fatty acid alcohol, particularly an NSAID as listed in categories 1 to 9 herein. Further, a method of preparation of a medicament for the treatment including prophylatic treatment of rheumatoid arthritis, osteoarthritis and related disorders; dysmenorrhoea; dementias, including Alzheimer's disease; or any other inflammatory or other conditions specified herein, wherein the said NSAID is used.

Abstract translation: 具有必需脂肪酸或必需脂肪酸醇的化合物形式的NSAID，特别是本文第1至9类中列出的NSAID。 此外，制备用于治疗的药物的方法，包括类风湿性关节炎的预防治疗，骨关节炎和相关疾病; 痛经 痴呆症，包括阿尔茨海默病; 或本文规定的任何其它炎症或其它病症，其中使用所述NSAID。

公开(公告)号：US5516800A

公开(公告)日：1996-05-14

申请号：US154481

申请日：1993-11-19

Applicant: David F. Horrobin

Inventor： David F. Horrobin

IPC: A61K31/20 ,  A61K31/201 ,  A61K31/202 ,  A61P25/18

CPC classification number: A61K31/20

Abstract: The negative symptoms of schizophrenia and/or low cell membrane levels of EFAs may be treated with a combination of arachidonic acid and docosahexaenoic acid.

Abstract translation: 精神分裂症和/或EFAs的低细胞膜水平的阴性症状可以用花生四烯酸和二十二碳六烯酸的组合来治疗。

公开(公告)号：US5378732A

公开(公告)日：1995-01-03

申请号：US981116

申请日：1992-11-25

Applicant: David F. Horrobin ,  John C. M. Stewart

Inventor： David F. Horrobin ,  John C. M. Stewart

IPC: A61K31/20 ,  A61K31/202 ,  A61P9/00 ,  A61P9/10 ,  C07C57/03 ,  C07C57/12

CPC classification number: A61K31/20 ,  Y10S514/824

Abstract: Gamma-linolenic acid and/or dihomo-gamma-linolenic acid is used in a medicament for reducing the rate of reocclusion of an artery from which an occlusion or other blockage has been removed, or for preventing occlusion of peripheral or coronary arteries. The medicament may also comprise eicosapentaenoic acid.

Abstract translation: γ-亚麻酸和/或二 - γ-亚麻酸用于降低动脉阻塞或其他阻塞已被除去的动脉或用于防止外周或冠状动脉闭塞的再闭塞速率的药物中。 药物还可以包含二十碳五烯酸。

公开(公告)号：US5318991A

公开(公告)日：1994-06-07

申请号：US51436

申请日：1993-04-22

Applicant: David F. Horrobin ,  Alfred C. Buck

Inventor： David F. Horrobin ,  Alfred C. Buck

IPC: A61K31/20 ,  A61K31/202 ,  A61P3/00 ,  A61P3/14 ,  A61P13/02 ,  A61P15/00 ,  A61P43/00

CPC classification number: A61K31/20

Abstract: Reduction of urinary calcium excretion in humans or animals by the administration of GLA or DGLA as much or in salt or other pharmacologically acceptable form, optionally in association with EPA, DHA or other EFA in similar forms, is also useful in the treatment of nephrocalcinosis, renal stones and osteoporosis.

Abstract translation: 通过给予GLA或DGLA或以任何与EPA，DHA或类似形式的其他EFA相关联的盐或其它药学上可接受的形式来减少人体或动物中的尿钙排泄也可用于治疗肾病， 肾结石和骨质疏松症。

公开(公告)号：US5276020A

公开(公告)日：1994-01-04

申请号：US990190

申请日：1992-12-14

Applicant: David F. Horrobin ,  John C. M. Stewart ,  Michael D. Winther

Inventor： David F. Horrobin ,  John C. M. Stewart ,  Michael D. Winther

IPC: C07D473/18 ,  A61K31/00 ,  A61K31/505 ,  A61K31/52 ,  A61K31/522 ,  A61K31/70 ,  A61K31/7042 ,  A61K31/7052 ,  A61K31/7064 ,  A61K31/7072 ,  A61P31/00 ,  A61P31/12 ,  C07D405/04 ,  C07D473/00 ,  C07H19/06 ,  C07H19/073 ,  C07H19/16 ,  C07H17/00

CPC classification number: C07D473/00 ,  C07H19/06 ,  C07H19/16

Abstract: Anti-virals wherein a linoleyl, gamma-linolenyl or other unsaturated long chain fatty acyl group is borne directly on a hydroxy or amino group of the sugar/sugar analogue or heterocyclic moiety of a nucleoside or nucleoside analogue.

Abstract translation: 其中亚油酰基，γ-亚麻醇基或其它不饱和长链脂肪酰基直接承载在核苷或核苷类似物的糖/糖类似物或杂环部分的羟基或氨基上的抗病毒剂。

公开(公告)号：US5246726A

公开(公告)日：1993-09-21

申请号：US871761

申请日：1992-04-21

Applicant: David F. Horrobin ,  Michel E. Begin

Inventor： David F. Horrobin ,  Michel E. Begin

IPC: A61K31/20 ,  A61K31/23 ,  A61K33/26

CPC classification number: A61K31/20 ,  A61K31/23 ,  A61K33/26

Abstract: Pharmaceutically acceptable compositions of one or more n-6 or n-3 essential fatty acids, particularly gamma-linolenic acid, dihomo-gamma-linolenic acid, or eicosapentaenoic acid, and assimilable iron compounds, in dosage unit form optionally with a diluent or carrier, said acids being present as such or as derivatives convertible in the body thereto and the amounts of said acids or derivatives being 1 mg to 100 g (calculated as gamma-linolenic acid) and of said iron compounds 0.1 mg to 10 g (calculated as iron) or submultiples of said amounts convenient for daily administration thereof.

Abstract translation: 一种或多种n-6或n-3必需脂肪酸，特别是γ-亚麻酸，二氢-γ-亚麻酸或二十碳五烯酸和可同化铁化合物的药学上可接受的组合物以剂量单位形式任选地含有稀释剂或载体 所述酸以本身的形式存在或作为在体内可转化为衍生物的衍生物，所述酸或衍生物的量为1mg至100g（以γ-亚麻酸计算）和所述铁化合物0.1mg至10g（以 铁）或所述量的次数便于日常给药。

公开(公告)号：US5198468A

公开(公告)日：1993-03-30

申请号：US717862

申请日：1991-06-19

Applicant: David F. Horrobin

Inventor： David F. Horrobin

IPC: A61K31/20

CPC classification number: A61K31/20

Abstract: Treatment or prevention of memory loss with a medicament consisting of an n-6 essential fatty acid selected from GLA, DGLA, AA, adrenic acid and the 22:5 n-6 acid and an n-3 essential fatty acid selected from the 18:4 n-3 and 20:4 n-3 acids, EPA, the 22:5 n-3 acid and DHA.

Abstract translation: 用由选自GLA，DGLA，AA，肾上腺素和22：5n-6酸和n-3必需脂肪酸的n-6必需脂肪酸组成的药物治疗或预防记忆丧失，其选自18： 4 n-3和20：4 n-3酸，EPA，22：5 n-3酸和DHA。